Compare JD.Com Inc (JD) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Nuwellis Inc — how do they compare? JD.Com Inc trades at $26.99 (market cap $36.51B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: JD.Com Inc is far larger — about 16595.5× Nuwellis Inc's market cap, and JD.Com Inc pays a 3.7% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Nuwellis Inc for 26 Days on average.
| JD | NUWE | |
|---|---|---|
Market Cap | $36.51B | $2.20M |
Volume | 7,051,146 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $146.65 |
52-Week Low | $25.19 | $0.68 |
Typical Hold Time | 85 Days | 26 Days |
Enterprise Value | $19.16B | -$1.52M |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $26.91, up 1.55% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.93 surpassing the $0.86 estimate. The company maintains robust fundamentals, including a low P/S ratio of 0.2 and a solid cash position of $234 billion as of 2024. Positive developments include potential EU approval for the $2.5 billion Ceconomy acquisition, signaling strategic expansion.
The outlook for JD.com is positive, supported by undervaluation metrics and strong free cash flow, though risks include revenue declines and regulatory scrutiny. With 69.57% of analysts rating it a Buy and a consensus price target of $35.86, the stock offers significant upside potential, but investors should monitor competitive pressures and macroeconomic headwinds in the Chinese market.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
